PET is an imaging technique that complements MRI and CT imaging. MRI and CT provide non-physiological, high-resolution anatomical images that can often reveal important information on the status of disease. Obtaining physiological information on diseased tissue can aid in diagnosis and help direct the proper course of treatment. PET is inherently based on physiological imaging. For PET a radionuclide is bound to a molecule of pharmacologic significance. The compound is administered and the images obtained with a PET scanner reveal localization of the pharmaceutical in the body.
Committed to PET imaging for drug development, drug radio-labeling and molecular tracer research, tumor targeted therapy technology, we will have implementation of platform construction for PET molecular imaging drug screening and preclinical evaluation. This platform will serve for global on medical imaging in the field of drug research. With the technology, knowledge and experience of the world’s leading professionals, we will use resources of small animal and non-human primates to create a novel method to establish PET imaging for drug screening in preclinical trials and clinical Phase 0 studies.
Phase 0 studies, also called micro-dosing studies, are a new regulatory category, guided by the EMEA (CPMP/SWP/2599/02, 2003) and FDA (Exploratory IND draft, 2005) allowing to perform human studies with a considerably reduced tox package, compared to a conventional first in human study, provided that not more than 100 µg substance are administered.
For CNS drug candidates, microdosing is of special interest to investigate BBB penetration, receptor binding, or dose-to-target-organ relationships. Also, first evidence on metabolism can be obtained. Microdosing represents a considerable cost and time advantage and helps to minimize attrition rates in CNS compound development.
PET & Pharmacology Studies
–With radioactive tracers, we can assess metabolic or synthetic rates of specific substance, thus allowing the evaluation of the functional status and integrity of the tissue.
–With radioactive ligands, we can be measure the concentration of specific receptor or transporter sites, thus allowing the evaluation of the integrity or distribution of specific targets that may correspond to their expression.
–With quantitative chamber analysis, we can be detect the potential confusion of blood flow differences.
△PET is used to predict the long-term efficacy of a drug
PET & PK Studies
Radioactive tracer labeled PET studies can quantitatively evaluate the pharmacokinetics and metabolism of drugs. Combined with pharmacodynamic data such as behavior, pharmacokinetic PET study can help researchers establish dose-response relationship and determine dosage. Additionally, PET can also track the distribution of drugs in target tissues.
△The target effect diagram of 64Cu labeled PD-1
△Left：Dynamic distribution of drugs in the abdominal cavity of mice
△Right：The drug is distributed across regions of the brain